NeoCerebellar Degeneration Paraneoplastic Profile with Recombx®

Test Code

91623

CPT Codes
83520 (x7), 86341

Includes

Amphiphysin Antibody Test
GAD65 Antibody Test, Recombx
MaTa Autoantibody Test, Recombx
CV2 Antibody Test, Recombx
Hu Autoantibody Test, Recombx
Ri Autoantibody Test, Recombx
Yo Autoantibody Test, Recombx
Zic4 Antibody Test

Preferred Specimen

2 mL serum

Minimum Volume

0.5 mL

Instructions

Note: Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.

Serum must be separated from cells within 48 hours of collection.

Transport Container

Plastic screw-cap vial

Transport Temperature

Refrigerated (cold packs)

Specimen Stability

Room temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days

Methodology
Automated Nanoliter Scale Immunoassay • Enzyme Linked Immunosorbent Assay (ELISA)

FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Set up: Mon, Wed, Fri; Report available: 7-10 days

Reference Range

See Laboratory Report

Clinical Significance

Anti-CV2, anti-Hu, anti-Ma, anti-Ta, anti-Ri, anti-Yo, anti-Zic4 antibodies, and anti-GAD65 are found in patients with acute or subacute symptoms of cerebellar degeneration including gait ataxia, nystagmus and/or dysarthria, and opsoclonus/myoclonus. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.